AstraZeneca’s (AZN) Buy Rating Reiterated at Berenberg Bank

Berenberg Bank reaffirmed their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a report published on Thursday morning,Digital Look reports. They currently have a £160 target price on the biopharmaceutical company’s stock.

AZN has been the subject of several other research reports. Citigroup upped their price objective on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Jefferies Financial Group restated a “buy” rating and set a £175 target price on shares of AstraZeneca in a report on Monday, August 3rd. Finally, Deutsche Bank Aktiengesellschaft restated a “sell” rating and issued a £115 price target on shares of AstraZeneca in a research report on Wednesday. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of £152.17.

Get AstraZeneca alerts:

View Our Latest Research Report on AstraZeneca

AstraZeneca Stock Down 1.2%

LON AZN opened at £120.06 on Thursday. The business has a fifty day moving average price of £125.70 and a 200 day moving average price of £136.70. The company has a debt-to-equity ratio of 64.10, a quick ratio of 0.59 and a current ratio of 0.89. The company has a market cap of £186.20 billion, a P/E ratio of 17.97, a P/E/G ratio of 0.86 and a beta of 0.21. AstraZeneca has a one year low of £107.84 and a one year high of £157.32.

AstraZeneca Company Profile

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Featured Articles

• Five stocks we like better than AstraZeneca
• Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
• Is Duolingo the Next Netflix-Style Comeback Story?
• GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
• GTA VI’s Console Problem Isn’t Take-Two’s Problem

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.